Figure 4 | British Journal of Cancer

Figure 4

From: Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts

Figure 4

Western blots of tumour lysates obtained from triplicate primary xenografts at the indicated time points following an acute single dose of NVP-BEZ235, 50 mg kg−1, probed with primary antibodies to: Ser473 Akt, Ser21/9 GSK3α/β, Ser235/236 S6 ribosomal protein, Thr37/46 4EBP-1, Tyr705 Stat3, with actin loading controls. Tumour NVP-BEZ235 concentrations for each sample are indicated, with the exception of those of insufficient size for this (ND).

Back to article page